Anthropic filed an S-1 for a Nasdaq IPO under the symbol ANT. It plans to expand into drug discovery with its own molecular biology lab. The company envisions AI matching top human experts in scientific fields. It aims to accelerate drug discovery, disease detection and personalized therapy. Anthropic already partners with Novo Nordisk, Bristol Myers Squibb and Novartis. It offers Claude for Life Sciences to support drug development workflows. The platform integrates with lab notebooks, databases and research tools. Anthropic acquired Coefficient Bio for $400 million to bolster life sciences research. It warns of scientific, regulatory and operational risks in drug development. AI errors could harm patients or compromise research. Regulators may require new authorizations or restrict applications. The FDA and other agencies could oversee its healthcare offerings. Anthropic’s AI was barred from use by U.S.
What changed
Anthropic was a software and AI research organization without its own molecular biology lab or direct drug discovery efforts.
What it unlocks
Operating laboratory equipment and robotic systems with AI agents for drug discovery.
- $100B potential IPO raise
- $2T target valuation
- $400M Coefficient Bio acquisition
- $2T 2026 global pharma spending
Sources